Léa Emonnot

Léa Emonnot is a medical lead specializing in oncology, focusing on lung cancer. They have previously served as a senior medical advisor at Takeda Oncology, where they were instrumental in the launch of Brigatinib and the development of the National Medical Strategy for lung cancer. Léa has collaborated extensively across departments, managing academic partnerships for both lung and head and neck cancer immunotherapy. They hold a postdoctoral degree in pharmacology from Université de Montréal and a PhD in cardiovascular pharmacology from Université Claude Bernard (Lyon I).